MSDx Announces Issuance of First Patent for Monitoring Disease Activity in a Multiple Sclerosis Patient

Desert Angels portfolio company MSDx, Inc., a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders, announced today that the United States Patent and Trademark Office issued a patent that broadly protects the company’s exclusive rights for monitoring or detecting Multiple Sclerosis (MS) in a patient, utilizing its proprietary technology.

For more: MSDx Announces Issuance of First Patent for Monitoring Disease Activity in a Multiple Sclerosis Patient